February 28, 2023
London, UK
Morgan Stanley – European MedTech & Services Conference
March 23, 2023
Bad Homburg, Germany
Annual Report 2022
Consolidated Financial Statements and Management Report (IFRS)
The Fresenius Group expresses its deepest sympathies and condolences to the families and individuals affected by the earthquakes in Türkiye and Syria.
As first reaction after the catastrophic event, the company fully focused on connecting with its patients in the region. People dependent on our lifesaving products and services were transferred in case of destruction of local infrastructure. As further immediate step, Fresenius Medical Care established contact with its employees on site and intensively looks into options to support its local staff and their families.
Our disaster response teams are in full action and are being supported by units from other parts of the country. As global healthcare company, Fresenius is committed to support with urgently needed medical supply and works with humanitarian aid organizations to deliver donations of its most critical care products and services.
We remain fully committed to our patients, local staff, and partners on site.
Fresenius Kabi’s innovative Ivenix Infusion System is recognized by KLAS Research in a Performance Insights First Look article. This report shares very positive customer experiences from health care organizations currently using the Ivenix Infusion System in the U.S. Ivenix, acquired in 2022 by Fresenius Kabi, offers a technologically advanced infusion system, including a large-volume pump, infusion management, software tools, applications, and analytics to inform care, advance efficiency, reduce infusion-related errors, and drive down the total cost of ownership.
Fresenius Kabi’s innovative Ivenix Infusion System is recognized by KLAS Research in a Performance Insights First Look article. This report shares very positive customer experiences from health care organizations currently using the Ivenix Infusion System in the U.S. Ivenix, acquired in 2022 by Fresenius Kabi, offers a technologically advanced infusion system, including a large-volume pump, infusion management, software tools, applications, and analytics to inform care, advance efficiency, reduce infusion-related errors, and drive down the total cost of ownership.
Fresenius Kabi has entered into a global license agreement to commercialize a Ustekinumab biosimilar candidate (FYB202) being developed by Formycon AG. The proposed biosimilar is currently in advanced clinical stage. FYB202 is a biosimilar candidate referencing Johnson & Johnson’s Stelara®*, a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. Stelara is approved for treatment of moderate-to-severe plaque psoriasis, Crohn’s disease, ulcerative colitis as well as active psoriatic arthritis. The global license agreement gives Fresenius Kabi exclusive rights to commercialize the proposed Ustekinumab biosimilar product in key global markets.
*Stelara® is a registered trademark of Johnson & Johnson
Fresenius Kabi has entered into a global license agreement to commercialize a Ustekinumab biosimilar candidate (FYB202) being developed by Formycon AG. The proposed biosimilar is currently in advanced clinical stage. FYB202 is a biosimilar candidate referencing Johnson & Johnson’s Stelara®*, a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. Stelara is approved for treatment of moderate-to-severe plaque psoriasis, Crohn’s disease, ulcerative colitis as well as active psoriatic arthritis. The global license agreement gives Fresenius Kabi exclusive rights to commercialize the proposed Ustekinumab biosimilar product in key global markets.
*Stelara® is a registered trademark of Johnson & Johnson